Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
228.87 M USD
259.17 M USD
64.49 M
About GALAPAGOS
Sector
Industry
CEO
Paulus Stoffels
Website
Headquarters
Mechelen
Founded
1999
FIGI
BBG000BJQY75
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.